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Abstract
Introduction: Hepatic dysfunction is a common finding in critically ill patients on the ICU and directly influences
survival. Liver stiffness can be measured by the novel method of transient elastography (fibroscan) and is closely
associated with hepatic fibrosis in patients with chronic liver disease, but also is increased in patients with acute
hepatitis, acute liver failure and cholestasis. We investigated liver stiffness as a potentially useful tool for early detection
of patients with hepatic deterioration and risk stratification with respect to short- and long-term mortality.
Methods: We prospectively evaluated 108 consecutive critically ill patients at our medical intensive care unit (ICU)
with subsequent longitudinal liver stiffness measurements (admission, Day 3, Day 7 and weekly thereafter) during
the course of ICU treatment. Outcome was followed after discharge (median observation time 237 days).
Results: Liver stiffness could be reliably measured in 71% of ICU patients at admission (65% at Day 3, 63% at Day
7). Critically ill patients (n = 108) had significantly increased liver stiffness compared to sex- and age-matched
standard care patients (n = 25). ICU patients with decompensated cirrhosis showed highest liver stiffness, whereas
other critical diseases (for example, sepsis) and comorbidities (for example, diabetes, obesity) did not impact
stiffness values. At admission to the ICU, liver stiffness is closely related to hepatic damage (liver synthesis,
cholestasis, fibrosis markers). During the course of ICU treatment, fluid overload (renal failure, volume therapy) and
increased central venous pressure (mechanical ventilation, heart failure) were major factors determining liver
stiffness. Liver stiffness values > 18 kilopascal (kPa) at ICU admission were associated with increased ICU and long-
term mortality, even in non-cirrhotic patients.
Conclusions: Considering that liver stiffness cannot be validly measured in about 30% of ICU patients, transient
elastography performed at ICU admission might be a useful tool to early identify liver dysfunction and predict
mortality in critically ill patients at a medical ICU.
Introduction
Transient elastography of the liver as evaluated by using
the FibroScan® (Echosens, Paris, France) instrument is a
non-invasive, fast and reproducible tool to assess hepatic
stiffness [1,2]. Liver stiffness is calculated from the pro-
pagation of an elastic shear wave induced by low ampli-
tude and frequency vibrations that is followed by pulse-
echo ultrasonographic acquisitions to measure the
velocity of the shear wave propagation. In principal, fast
shear wave propagation indicates increased liver stiffness
[1]. A strong association of liver stiffness and the degree
of liver fibrosis has been demonstrated in various
patients with chronic liver diseases, mainly with chronic
hepatitis C and non-alcoholic fatty liver diseases [1,3-5].
Its advantage compared to liver biopsy is its fast applic-
ability and non-invasiveness [6]. Importantly, besides
FibroScan® (EchoSens), other elastography techniques
exist as well, including acoustic radiation force impulse
(ARFI, Siemens, Erlangen, Germany), which combines
conventional ultrasound and local liver stiffness, as well
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as similar approaches by supersonic shear imaging (SSI),
real-time elastography (RT-E, Hitachi, Wiesbaden, Ger-
many) and shearwave dispersion ultrasound vibrometry
(SDUV), or, alternatively, Magnetic Resonance Elasto-
graphy (MRE), which is based on the MRI detection of
acoustic shear waves progressing through the liver tissue
[7-11]. Most of the studies evaluating transient elasto-
graphy focussed on patients with chronic liver diseases
in a stable, standard care setting, except for a very few
studies performed in patients with either acute hepatic
diseases (acute hepatitis, acute liver failure) or acute
decompensation of chronic liver disease [12,13]. At pre-
sent, no systematic examination exists for critically ill
patients without a distinct hepatic disease.
In critically ill patients with multiple organ failure, liver
dysfunction is very common, as reflected, for instance, by
an incidence of 30 to 40% for jaundice in the intensive
care unit (ICU) [14,15]. Importantly, liver function is
clearly linked to survival in the critically ill [16], as it has
been included in most of the widely used clinical multifac-
torial scoring systems for risk stratification in the ICU set-
ting, for example, Acute Physiology and Chronic Health
Evaluation (APACHE-II, cirrhosis as a factor) or Sequen-
tial Organ Failure Assessment (SOFA, bilirubin and inter-
national normalized ratio (INR) as components) [17].
However, liver dysfunction in the critically ill may be
underrated, being more subtle in its clinical presentation
and less immediately life-threatening than respiratory, car-
diovascular or renal failure [15]. Sophisticated measures
such as indocyanine green (ICG) plasma disappearance
rate that reflect liver perfusion and function in the criti-
cally ill are only available in a few specialized centers [18].
We hypothesized that transient elastography could be
a useful tool for the early identification of hepatic dys-
function in critically ill patients without underlying
known liver disease and for appropriate risk stratifica-
tion with respect to ICU and long-term mortality.
Materials and methods
Patients and controls
The study protocol conformed to the ethical guidelines
of the 1975 Declaration of Helsinki as reflected in a
priori approval by the local ethics committee. Written
informed consent was obtained from the patient, his or
her spouse or the appointed legal guardian. We exam-
ined 108 patients who were admitted consecutively to
the medical intensive care unit at RWTH-University
Hospital Aachen, Germany, due to critical medical dis-
eases (Table 1). Patients who were expected to have a
short-term (<72 h) intensive care treatment due to post-
interventional observation or acute intoxications were
not included in the study [19]. Decompensated liver cir-
rhosis was a clinical diagnosis established by two inde-
pendent experienced hepatologists based on the
patient’s history (for example, history of cirrhosis or
typical cirrhosis-related comorbidities, such as esopha-
geal varices, variceal bleeding, ascites, hepatic encepha-
lopathy or hepatocellular carcinoma), laboratory values
and hepatic imaging (ultrasound, CT, MRI) [20]. Sepsis
was defined according to the criteria proposed by the
American College of Chest Physicians and the Society of
Critical Care Medicine Consensus Conference Commit-
tee for severe sepsis and septic shock [19]. None of the
patients showed signs of intra-abdominal hypertension
or underwent abdominal surgery. The clinical course of
patients was observed in a follow-up period (median
observation time 237 days, interquartile range 162 to
350 days) by directly contacting the patients, the
patients’ relatives or their primary care physician [21].
As a control population, 25 sex- and age-matched
patients from our standard care unit with various medi-
cal diseases, mostly pneumonia or cardiovascular disor-
ders, were examined. Control patients had no evidence
of chronic liver diseases (normal liver enzymes, negative
serology for viral hepatitis, and regular liver appearance
in abdominal ultrasound).
Routine and experimental laboratory parameters
Patient data, clinical information, blood samples and
liver stiffness measurements were collected prospec-
tively. Patients were physically examined daily. Presence
of ascites was defined as: (1) none (by ultrasound), (2)
moderate (only detectable by ultrasound), (3) massive
(already apparent on clinical examination). Furthermore,
the presence of peripheral edema (pitting > 2 mm at the
lower leg) was assessed, but not quantified. The follow-
ing experimental parameters were determined from
stored serum/plasma samples of all patients and three
individual time-points (admission, Day 3, Day 7) accord-
ing to manufacturers’ instructions: coagulation factor
VII (STA compact, Roche, Mannheim, Germany, as a
marker of liver synthesis function), hyaluronic acid
(latex agglutination method, Wako Diagnostics, Osaka,
Japan, adapted on cobas e601, Roche; as a serological
marker for hepatic fibrosis) [22], cystatin C (BN II, Sie-
mens; as a marker of renal function), NT-proBNP
(Modular analytics e170, Roche; as a marker of cardiac
function), TNF-alpha (Immulite, Siemens; as a marker
of systemic inflammation), and procalcitonin (cobas
e411, Roche; as a marker of bacterial infections) [20].
Liver stiffness measurements
Liver stiffness measurement was performed by transient
elastography using the FibroScan® instrument (EchoSens),
which employs the propagation of an elastic shear wave
delivered by a vibrating probe [6]. This shear wave is fol-
lowed by an ultrasound wave, and their velocity is mea-
sured to determine the elasticity of the liver, expressed in
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kilopascal (kPa). Per patient, two median liver stiffness
measurements at two positions, each consisting of at least
10 individual, valid measurements with a success rate ≥
60%, were assessed per time-point. If the interquartile
range of the valid measurements exceeded 25%, variance
was regarded as too high, and values were not deemed
reliable. For subsequent statistical analyses, the median of
both (median) liver stiffness measurements was employed.
All measurements were performed with the ‘M probe’
(EchoSens). In order to minimize confounding effects due
to operator variability, all measurements were performed
by one specifically trained, experienced investigator, who
was not involved in patient management and blinded to
disease etiology. Liver stiffness was assessed at the admis-
sion day (within 16 hours after admission to the ICU) and
subsequently at Days 3 and 7 during ICU treatment. Con-
secutively, liver stiffness was then measured weekly in par-
ticipating patients.
Statistical analysis
Data are given as median and interquartile ranges (25th to
75th percentile) due to the skewed distribution of most
parameters. Differences between two groups were assessed
by Mann-Whitney-U-test and multiple comparisons
between more than two groups by Kruskal-Wallis-ANOVA
and Mann-Whitney-U-test for post hoc analysis [19]. Box
plot graphics illustrate comparisons between subgroups,
displaying a statistical summary of median, quartiles, range
and extreme values. The whiskers extend from the mini-
mum to the maximum value excluding outside (indicated
by open circles) and far out values (asterisks), which are
displayed as separate points [23]. Correlations between
variables have been analyzed using the Spearman correla-
tion tests, where values of P < 0.05 were considered statisti-
cally significant [24]. Kaplan-Meier curves were plotted to
display the impact of liver stiffness measurements on survi-
val. Comparisons of Kaplan-Meier analyses were performed
by log rank tests [25]. Optimal cut-off prognostic values for
liver stiffness were determined by comparing various log
rank tests, testing stiffness values from 12 to 22 [26]. All
statistical analyses were performed with SPSS version 12
(SPSS Inc., Chicago, IL, USA)
Results
Validity of liver stiffness measurements in critically ill
medical patients
Liver stiffness is believed to comprise a sum result of
hepatic edema, cholestasis and organ fibrosis [12].
Table 1 Baseline patient characteristics and liver stiffness measurements
Parameter All patients Sepsis Non-sepsis
Number 108 80 28
Sex (male/female) 64/44 50/30 14/14
Age median (range) (years) 68
(21 to 90)
68
(21 to 90)
61
(35 to 85)
APACHE-II score median (IQR) 22
(15 to 27)
23
(17 to 28)
19
(7 to 22)
SOFA score median (IQR) 11
(6 to 13)
11
(8 to 14)
9
(1 to 11)
ICU days median (IQR) 9.5
(4 to 26)
13.0
(5 to 28)
7.0
(3 to 16)
Death during ICU n (%) 23 (21%) 20 (25%) 3 (11%)
Death during follow-up n (%) 48 (44%) 41 (51%) 7 (25%)
Mechanical ventilation n (%) 83 (77%) 64 (80%) 19 (68%)
Ventilation time median (IQR) (h) 188
(1 to 1846)
229
(48 to 492)
99
(2 to 312)
pre-existing liver cirrhosis n (%) 8 (7%) 3 (4%) 5 (18%)
ascites (US*) moderate/massive n (%) 11 (10%)/
6 (6%)
4 (5%)/
3 (4%)
7 (25%)/
4 (5%)
pre-existing diabetes n (%) 32 (30%) 21 (26%) 11 (39%)
BMI median (range)
(m2/kg)
26.0
(22.7 to 29.1)
25.1
(22.5 to 28.2)
26.5
(24.3 to 32.5)
liver stiffness Day 1 median (IQR) (kPa) 9.7
(7.0 to 17.1)
11.0
(7.5 to 18.1)
9.4
(6.3 to 12.2)
liver stiffness Day 3 median (IQR) (kPa) 9.4
(7.3 to 17.7)
10.0
(7.4 to 18.2)
8.4
(6.8 to 27.2)
liver stiffness Day 7 median (IQR) (kPa) 10.1
(6.3 to 18.8)
8.7
(6.1 to 17.4)
11.9
(7.9 to 41.7)
For quantitative variables, median and interquartile range (IQR) (in parenthesis) are given. Abbreviations are: APACHE, Acute Physiology and Chronic Health
Evaluation; BMI, body mass index; ICU, intensive care unit; SOFA, sequential organ failure assessment; *ascites detected by abdominal ultrasound (US).
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However, large studies revealed that liver stiffness mea-
surements fail in about one-fifth of hepatologic patients
due to technical reasons in a standard care setting [6].
We examined critically ill patients at a medical ICU in
order to evaluate liver stiffness measurements (a) to
assess liver function in critical illness and its potential
clinical impact, (b) possible prognostic power to predict
mortality, and (c) practicability and limitations of transi-
ent elastography in intensive care medicine. Therefore,
we integrated liver stiffness measurements in the clinical
evaluation of critically ill medical patients by assessing
stiffness at the admission day, Day 3, Day 7 and, subse-
quently, weekly during the ICU course (Figure 1). A
total of 108 patients were included in our study at
admission, with subsequently lower patient numbers at
follow-up measurements due to deaths or transfers from
the ICU to standard care (Figure 1).
In principal, liver stiffness could be validly measured
in 71% of the patients at admission day to the ICU (Fig-
ure 1). However, during the course of ICU treatment,
involving aggressive fluid challenge, vasopressors, inva-
sive mechanical ventilation and further ongoing severe
organ function deterioration [26], the rate of successful
liver stiffness measurements decreased to 65% at Day 3
and to 63% at Day 7, respectively (Figure 1). Patients
with invalid liver stiffness measurements revealed char-
acteristic features, such as higher body mass index
(BMI), obesity (that is, BMI > 25 kg/m2) and peripheral
edema (Table 2). Measurability was not affected by the
disease etiology leading to ICU admission nor by
patient’s sex. In line with findings reported from stan-
dard care patients [6], the rate of invalid stiffness mea-
surements was higher in older ICU patients (Table 2).
Liver stiffness is increased in critically ill patients, with
highest values in decompensated liver cirrhosis, but
independent of sepsis
Based on the validity of liver stiffness measurements in
the vast majority of ICU patients, independent of the
underlying diagnosis, we next investigated its clinical
value in critically ill patients. In comparison to standard
care patients without liver disease (as a control cohort),
ICU patients had significantly higher liver stiffness
values (median 5.0 kPa in controls versus 9.7 kPa in
ICU patients, P < 0.001, Figure 2A). ICU patients with
decompensated liver cirrhosis showed highest liver stiff-
ness values as compared with critically ill patients with-
out cirrhosis (Figure 2B). In decompensated cirrhosis,
liver stiffness was found to range from 59 to 75 kPa,
thus by far exceeding the average of non-cirrhotic ICU
patients (Figure 2B), and confirming prior observations
on patients with decompensated liver cirrhosis [1,27].
Cirrhosis and sepsis are both characterized by a hyper-
dynamic circulation associated with a low systemic
vascular resistance and the release of many pro-inflam-
matory mediators [28]. We, therefore, analyzed whether
liver stiffness values can discriminate between septic-
and non-septic patients. No difference could be detected
between sepsis and non-sepsis patients in liver stiffness
at admission (Figure 2C, Table 1); this was also observed
when only the non-cirrhotic patients (n = 100) were
included in the analysis (data not shown). In an exten-
sive subgroup analysis, septic patients with an abdom-
inal site of infection demonstrated higher liver stiffness
values in comparison to patients with pulmonary origin
of sepsis (Figure 2D). Moreover, in patients with chronic
liver diseases, type 2 diabetes or obesity were identified
as possible confounders for transient elastography values
[3,6]. In our cohort, pre-existing type 2 diabetes or obe-
sity (defined as BMI > 25 kg/m2) did not significantly
influence liver stiffness, neither in the total cohort (Fig-
ure 2E, F) nor for the non-cirrhotic subgroup (data not
shown).
Liver stiffness measurements reflect hepatic function
upon admission to the ICU, but non-hepatic organ failure
in follow-up examinations during ICU treatment
The marked increase of liver stiffness in all critically ill
patients and the maximally elevated values in the sub-
group of patients with decompensated cirrhosis, led us
to hypothesize that transient elastography examinations
at admission to the ICU reflect deterioration of liver
function in the critically ill. In fact, liver stiffness at
admission was strongly correlated with biomarkers of
hepatic synthesis capacity, such as coagulation factor VII
activity (Figure 3A), pseudocholinesterase activity (Fig-
ure 3B) or international normalized ratio (Table 3).
Liver stiffness also correlated with biomarkers of chole-
static damage, namely gamma-GT (Figure 3C), bilirubin
and alkaline phosphatase (Table 2). As the critically ill
might have pre-existing unrecognized hepatic fibrosis,
we also measured hyaluronic acid as a non-invasive bio-
marker of fibrosis [2,20]. Liver stiffness correlated with
hyaluronan serum concentrations in ICU patients (Fig-
ure 3D, Table 3).
Unexpectedly, most of these associations between
hepatic organ function and liver stiffness could not be
reproduced anymore at the follow-up measurements at
Days 3 and 7 during the course of intensive care treat-
ment. Surprisingly, liver stiffness was then associated
with non-hepatic organ functions, specifically with renal
failure (Figure 4A, Table 3), pulmonary dysfunction as
mirrored by parameters of mechanical ventilation (Table
3) and with circulatory impairment summarizing heart
failure and volume load, by the means of vasopressor
demand, net fluid balance, NT-proBNP serum concen-
trations and central venous pressure (Figure 4B, C,
Table 3). The median volume of fluid resuscitation that
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Figure 1 Liver stiffness measurements in the intensive care unit (ICU) setting. Critically ill medical patients were included into this study
upon admission to the ICU. Transient liver elastography was assessed at admission, on Day 3, on Day 7, and subsequently once per week. The
setting of our study is displayed in the upper panel; stiffness measurements were performed at the bedside with a portable FibroScan®
apparatus, alongside classical hemodynamic and respiratory monitoring as well as typical ICU treatment measures. The numbers of patients
included into the study and the numbers of ICU patients with valid liver stiffness measurements are given in the lower panel of the figure. The
numbers of drop-outs, due to transferral to standard care or death, are also displayed.
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was administered within 24 hours to the patients of our
cohort was 6,207 ml (IQR 4,746 to 8,048) at admission
day, 4,494 ml (IQR 3,812 to 5,577) at Day 3 and 3,801
ml (IQR 3,298 to 4,471) at Day 7. At all time-points
within the first week of ICU treatment, liver stiffness
was significantly correlated with clinical composite
scores (that is, APACHE-II, SOFA) commonly used at
the ICU to determine disease severity (Table 3).
Liver stiffness values at admission predict ICU- and
overall mortality in critically ill patients
Based on the significant correlations between clinical
composite scores and liver stiffness values, we examined
whether transient elastography examinations could be
useful in predicting ICU- or overall-mortality. Indeed,
patients with liver stiffness values of the upper quartile
(corresponding to values > 17 kPa) had an increased
short-term mortality at the ICU as compared to patients
with liver stiffness values of lower quartile or middle
50% (Figure 5A). After testing different possible cut-off
values for liver stiffness by Kaplan-Meier curves and
log-rank test calculations, a transient elastography value
of 18 kPa was found to discriminate best between ICU
survivors and ICU non-survivors, when obtained at ICU
admission (Figure 5B). In order to rule out potential
confounding effects by patients with decompensated
liver cirrhosis and extremely high liver stiffness, we con-
firmed this finding in the critically ill patients after
exclusion of decompensated cirrhosis (Figure 5C). How-
ever, subsequent liver stiffness measurements at Days 3
and 7 during ICU treatment did not reveal this prognos-
tic relevance to predict ICU mortality (Figure 5D, E).
Furthermore, individual changes of liver stiffness (’delta
stiffness’) within the first week of ICU treatment were
not indicative of prognosis either (data not shown).
In our cohort, 21% of the critically ill patients died
during the course of ICU treatment and an additional
23% died within the first year after discharge from the
Table 2 Validity of liver stiffness measurements in critically ill patients*.
Liver stiffness measurements P-value
valid not valid
ICU admission n (%) 77 (71%) 31 (29%)
sex (male/female, %) 64%/36% 48%/52% n.s.
age median (range) years 64 (21 to 90) 72 (39 to 89) 0.037
body mass index median (range) kg/m2 24.5 (15.9 to 52.2) 31.2 (22.2 to 66.7) < 0.001
body mass index > 25 kg/m2 39% 87% < 0.001
diabetes (%) 31% 34% n.s.
sepsis (%) 75% 71% n.s.
ICU survival/death (%) 79%/21% 77%/23% n.s.
peripheral edema (%) 30% 58% 0.002
ICU Day 3 n (%) 62 (65%) 33 (35%)
sex (male/female, %) 68%/32% 48%/52% n.s.
age (median years) 65 (21 to 90) 71 (39 to 89) n.s.
body mass index (median kg/m2) 24.0 (15.9 to 52.2) 31.2 (22.5 to 66.7) < 0.001
body mass index > 25 kg/m2 (%) 32% 89% < 0.001
diabetes (%) 28% 36% n.s.
sepsis (%) 79% 70% n.s.
ICU survival/death (%) 84%/16% 78%/22% n.s.
peripheral edema (%) 25% 63% < 0.001
ICU Day 7 n (%) 43 (63%) 25 (37%)
sex (male/female, %) 65%/35% 56%/44% n.s.
age (median years) 65 (21 to 87) 71 (24 to 67) n.s.
body mass index (median kg/m2) 23.6 (18.3 to 29.3) 31.2 (24.0 to 66.7) < 0.001
body mass index > 25 kg/m2 (%) 26% 92% < 0.001
diabetes (%) 21% 55% 0.008
sepsis (%) 86% 64% 0.037
ICU survival/death (%) 88%/12% 88%/12% n.s.
peripheral edema (%) 29% 61% 0.022
*Validity of measurements meant the following: 10 measurements each (technical success rate > 60%) from two different anatomical positions and each
interquartile range < 25%. From these 2 × 10 measurements, the median of both median values was obtained. If any of these requirements was not met (for
example, only one probe position possible, very low success rate at a distinct position, high variance of obtained values, and so on), the liver stiffness value was
not considered valid.
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Figure 2 Liver stiffness in critically ill patients with different disease etiologies at ICU admission. (A) ICU patients have significantly
higher liver stiffness values as compared with standard care (control) patients. (B) ICU patients with decompensated liver cirrhosis display
highest stiffness values. (C) Liver stiffness does not differ between sepsis and non-sepsis patients. (D) In the subgroup of sepsis patients, patients
with an abdominal site of infection show higher liver stiffness than patients with sepsis of pulmonary origin. (E-F) Pre-existing type 2 diabetes or
obesity (BMI > 25 kg/m2) does not affect liver stiffness in ICU patients. P-values from U-test are given in the figure.
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ICU during the observation period of our study (Table
1). Also, for ‘long-term’ survival, liver stiffness measure-
ments > 18 kPa upon admission to the ICU predicted
mortality in the total patient group (Figure 6A) as well
as in non-cirrhotic ICU patients (Figure 6B). Again, liver
stiffness obtained in longitudinal measurements at Day
3 or Day 7 of ICU treatment did not predict long-term
mortality (Figure 6C, D). Overall, transient liver elasto-
graphy examinations performed at admission to the ICU
appeared capable of identifying patients being at high
risk by means of short- and long-term survival.
Discussion
The measurement of liver stiffness by transient elasto-
graphy has been recently introduced for the assessment
of hepatic fibrosis in patients with chronic liver diseases
[1]. So far, it has been mostly validated for viral hepatitis
and non-alcoholic fatty liver disease [1-3]. As of yet, no
Figure 3 Liver stiffness in critically ill patients at ICU admission reflects hepatic organ damage. Liver stiffness values at admission are
significantly correlated with biomarkers of hepatic synthesis function (factor VII, A) pseudocholinesterase, B), cholestasis (gamma-
glutamyltransferase, C) and organ fibrosis (hyaluronic acid, D). Correlation coefficient (r) from Spearman rank correlation test and P-values are
given in the figure.
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systematic analysis has examined liver stiffness measure-
ments in critically ill patients, in which the liver is often
compromised due to different reasons, such as endotox-
emia, circulatory alterations (cardiac failure or hyperdy-
namic state) or exogenous factors (for example,
increased intraabdominal or intrathoracic pressure due
to impending abdominal compartment or mechanical
ventilation, respectively) [28]. Our study revealed that
critically ill patients admitted to a medical ICU have sig-
nificantly elevated liver stiffness compared to standard-
care control patients. In line with current literature [29],
extremely high values were found in patients with
decompensated cirrhosis. Remarkably, the median liver
stiffness of non-cirrhotic ICU patients reached values of
about 10 kPa, which is commonly regarded as a sign of
severe hepatic fibrosis in non-ICU patients [5]. A total
of 33% of our medical, non-cirrhotic ICU patients even
presented themselves with values > 12.5 kPa at admis-
sion, which would otherwise indicate established liver
cirrhosis [5].
Smaller studies on selected patient groups have sug-
gested that liver stiffness in patients with acute decom-
pensation might rapidly increase and not reflect hepatic
fibrosis per se. For instance, patients with acute hepatitis
or acute liver failure showed significantly elevated liver
stiffness, which decreased after recovery and might be
attributed to inflammatory infiltrates in the liver
[12,13,30]. Patients with severe cholestasis resulting in
increased intrahepatocytic pressure due to impaired bile
flow also have elevated liver stiffness values [31]. Vascu-
lar factors may also influence liver stiffness measure-
ments, as these values directly correlate with the hepatic
Table 3 Correlations with liver stiffness measurements
Liver stiffness measurements
Admission Day 3 Day 7
r P r P r P
Hepatic organ function
Liver synthesis
F VII -0.365 0.002 -0.282 0.034 - n.s.
PCHE -0.487 < 0.001 -0.376 0.009 - n.s.
INR 0.399 < 0.001 - n.s. - n.s.
AT III -0.299 0.012 - n.s. - n.s.
Cholestasis
bilirubin 0.489 < 0.001 - n.s. 0.415 0.008
gamma-GT 0.330 0.003 - n.s. 0.343 0.030
AP 0.355 0.005 - n.s. - n.s.
Liver fibrosis
hyaluronan 0.415 0.001 - n.s. - n.s.
Non-hepatic
organ function
Kidney
cystatin C - n.s. 0.273 0.044 0.367 0.030
cystatin C GFR - n.s. -0.276 0.042 -0.377 0.026
Lung
ventilation time - n.s. 0.332 0.011 0.573 < 0.001
PiP 0.423 0.001 - n.s. - n.s.
PEEP 0.413 0.001 - n.s. - n.s.
Circulation
noradrenalin dose 0.286 0.013 - n.s. 0.349 0.037
NT-proBNP - n.s. 0.284 0.032 0.478 0.002
CVP - n.s. - n.s. 0.553 0.003
net fluid balance - n.s. - n.s. 0.332 0.045
Overall disease severity
APACHE II score 0.350 0.007 0.304 0.040 0.413 0.023
SOFA score 0.324 0.016 - n.s. 0.562 0.003
r, correlation coefficient; P, P-value (r and P-values by Spearman rank correlation); only significant correlations are shown. Abbreviations are: AP, alkaline
phosphatase; APACHE, Acute Physiology and Chronic Health Evaluation; AT III, antithrombin III; CRP, C-reactive protein; CVP, central venous pressure; F VII, factor
VII; gamma-GT, gamma-glutamyl-transferase; GFR, glomerular filtration rate; ICU, intensive care unit; INR, international normalized ratio; PiP, positive inspiratory
pressure; PCHE, pseudocholinesterase; PEEP, positive endexpiratory pressure; SOFA, sequential organ failure assessment
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venous pressure gradient (HVPG) in patients with portal
hypertension [29]. More recently, additional liver-unre-
lated extrahepatic factors influencing liver stiffness have
been identified. By clamping the inferior cava vein in
landrace pigs, central venous pressure was found to cor-
relate linearly with liver stiffness [32]. Concordantly,
patients with decompensated chronic heart failure also
demonstrated high liver stiffness in a small clinical trial
[33]. On the other hand, extensive pressure within the
liver as reflected by high liver stiffness values might trig-
ger fibrogenic responses in the liver as well, such as
activation of hepatic stellate cells and their transdifferen-
tiation into collagen-producing myofibroblasts [34].
In our cohort of critically ill patients from a medical
ICU, likely a combination of the above mentioned fac-
tors contribute to significantly increased liver stiffness
values. However, by simultaneously assessing a wide set
of biomarkers and clinical parameters in a large well-
Figure 4 Liver stiffness after one week of ICU treatment is associated with non-hepatic organ damage. Liver stiffness values at Week 1
are significantly correlated with biomarkers of renal function (cystatin C-calculated glomerular filtration rate, A), heart failure (NT-proBNP, B) and
central venous pressure (CVP, C). Correlation coefficient (r) from Spearman rank test and P-values are given in the figure.
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characterized patient population, we were able to unra-
vel distinct predominant factors associated with liver
stiffness at different time-points in the course of ICU
treatment. At admission to the ICU, transient elastogra-
phy largely reflected hepatic organ dysfunction, as
revealed by correlations with biomarkers of liver synth-
esis, cholestasis and fibrosis. These findings are surpris-
ingly analogous to observations from patients with acute
liver failure [12], possibly suggesting that the pathome-
chanisms affecting hepatic organ function in non-cirrho-
tic ICU patients are very similar to those in acute liver
failure (for example, hepatic edema, reduced hepatic
blood flow, cholestasis, extracellular matrix deposition).
Therefore, implementing transient elastography exami-
nations into the assessment of critically ill patients at
admission could potentially help to early identify affec-
tion of the liver related to critical diseases.
The implication of elevated liver stiffness in medical
ICU patients substantially changed during the course of
intensive care treatment, which is usually characterized
by high-volume fluid substitution, vasopressor adminis-
tration and organ replacement therapies, such as
mechanical ventilation and continuous veno-venous
hemofiltration [26]. At Days 3 and 7, parameters of
non-hepatic organ function, namely kidney, lung and
heart/circulation, were correlated with liver stiffness, but
liver stiffness was not closely associated with biomarkers
of hepatic function anymore. Likely, these associations
can be referred to two major pathogenic mechanisms:
(a) fluid overload due to therapeutic measures and renal
failure, and (b) elevated central venous pressure caused
by positive pressure ventilation and impaired cardiac
function. The latter mechanism has been proposed by
two smaller studies in patients with decompensated
Figure 5 Prediction of ICU mortality by increased liver stiffness at admission. (A) Kaplan-Meier survival curves of ICU patients are displayed,
showing that patients with liver stiffness values of the upper quartile (> 17 kPa, black) at admission have an increased mortality at the ICU as
compared to patients with liver stiffness of the lower quartile (< 7 kPa, grey) or of the middle 50% (dotted line). P-values and log-rank tests are
given in the figure. (B) Analysis as in A, using a cut-off liver stiffness of 18 kPa (black line: > 18 kPa, grey line: < 18 kPa). (C) Analysis as in B,
excluding the ICU patients with decompensated liver cirrhosis. (D-E) Liver stiffness measurements at Days 3 or 7 do not predict ICU mortality.
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heart failure, in which liver stiffness was correlated to
reduced left ventricular ejection fraction and pathologi-
cally elevated NT-proBNP serum levels [32,33], as also
seen in our study.
Besides identifying factors influencing liver stiffness in
critical illness, we provided evidence that transient
elastography measurements were clinically relevant for
predicting mortality in a prospective setting. Patients
with liver stiffness values > 18 kPa had significantly
reduced survival rates not just during the course of ICU
treatment, but also in long-term observation. Apart
from our study, data on the prognostic value of
Figure 6 Prediction of long-term mortality by increased liver stiffness at admission. (A) Kaplan-Meier survival curves of ICU patients are
displayed, showing that patients with liver stiffness > 18 kPa (black) at admission have an increased long-term mortality during follow-up as
compared to patients with liver stiffness values < 18 kPa (grey). P-values and log-rank tests are given in the figure. (B) Analysis of A, excluding
the ICU patients with decompensated liver cirrhosis. (C-D) Liver stiffness measurements at Days 3 or 7 do not predict long-term mortality.
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transient elastography for predicting ‘hard end-points’,
such as mortality, are very limited. One recent study
demonstrated that high liver stiffness indicates poor sur-
vival in patients with hepatitis C [35]. In addition, an
association of high liver stiffness with development of
hepatocellular carcinoma and mortality has been
reported in patients with HBeAg-negative hepatitis B
[36]. In patients with various chronic liver diseases, tran-
sient elastography was found to predict the occurrence
of complications related to portal hypertension [29].
Limitations of the study
Some limitations of our study need to be considered.
First, we cannot provide liver histology from our ICU
patients, as there has been no clinical necessity to per-
form liver biopsies in this critically ill patient cohort. In
order to overcome this potential short-coming (lack of
liver histology), we had included hyaluronic acid as a
serological fibrosis marker. Second, data on possible
associations between extensive hemodynamic monitor-
ing and liver stiffness are lacking, as echocardiography,
pulmonary artery catheterization or Pulse Contour Car-
diac Output (PiCCO) recording were only performed in
a subgroup of our patients, which did not allow suffi-
cient statistical analysis. Therefore, further studies are
warranted focussing on hepatic dysfunction, potentially
also as a therapeutic target, in critical illness. Another
possibly relevant aspect for clinical applicability of this
technique is that the measurements in our cohort have
been performed by a single investigator in order to
exclude confounding inter-observer effects. However,
feasibility of liver stiffness measurements in clinical
practice, when performed by multiple less experienced
investigators, might be lower than anticipated from our
study. Of note, a different probe for obese patients (’XL
probe’) has been recently released by the distributor of
the FibroScan® apparatus, which might possibly help
increase the number of ICU patients that could be
validly measured by transient elasography. Alternatively,
other techniques assessing liver stiffness might be tested
in the ICU setting as well, for example, ultrasound-
based ARFI detection, because some of these techniques
might have a higher success rate, especially in the pre-
sence of edema or ascites [7,37]. Moreover, we would
like to stress that the potential threshold of 18 kPa for
liver stiffness upon ICU admission needs to be prospec-
tively validated in an independent cohort with respect to
relevant outcome measures.
Conclusions
We herein prove for the first time the applicability of
transient elastography in a large and well-characterized,
prospectively analyzed cohort of critically ill medical
patients. Liver stiffness reflects several aspects of hepatic
organ function when measured upon ICU admission.
During the course of intensive care treatment measures,
fluid overload and increased central venous pressure are
major factors determining liver stiffness. Considering
that liver stiffness cannot be validly measured in about
30% of ICU patients, transient elastography performed
at ICU admission might be a useful tool to predict mor-
tality in critically ill, even in non-cirrhotic patients, and
further prospective validation studies using the identified
cut-off values should be performed. This evident link
between mortality and liver stiffness emphasizes that
affection of the liver is common in critical disease and is
decisive for the patient’s individual chance of survival.
Key messages
• Measuring liver stiffness by transient elastography
is a novel tool commonly used by hepatologists to
assess hepatic fibrosis in patients with chronic liver
diseases, and comprises a sum result of hepatic
edema, cholestasis and organ fibrosis
• In a large prospective study measuring liver stiff-
ness repetitively during the course of ICU treatment,
critically ill patients without known liver disease had
significantly elevated liver stiffness, reaching levels
commonly observed in advanced hepatic disease,
and showed the highest values in decompensated
liver cirrhosis
• At admission to the ICU, liver stiffness is closely
related to hepatic damage (liver synthesis, cholesta-
sis, fibrosis), but during the course of ICU treatment,
fluid overload (renal failure, volume therapy) and
increased central venous pressure (mechanical venti-
lation, heart failure) are major factors determining
liver stiffness
• Liver stiffness values > 18 kPa at ICU admission
were associated with increased ICU and long-term
mortality (observation period about one year), indi-
cating that transient elastography performed at ICU
admission might be a valid tool for the early identifi-
cation of liver dysfunction and the prediction of
mortality in critically ill medical patients
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